A detailed history of Avidity Partners Management LP transactions in Exact Sciences Corp stock. As of the latest transaction made, Avidity Partners Management LP holds 588,000 shares of EXAS stock, worth $29.1 Million. This represents 2.46% of its overall portfolio holdings.

Number of Shares
588,000
Previous 338,500 73.71%
Holding current value
$29.1 Million
Previous $14.3 Million 179.95%
% of portfolio
2.46%
Previous 0.7%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$42.43 - $70.83 $10.6 Million - $17.7 Million
249,500 Added 73.71%
588,000 $40 Million
Q2 2024

Aug 14, 2024

BUY
$41.33 - $74.26 $14 Million - $25.1 Million
338,500 New
338,500 $14.3 Million
Q4 2021

Feb 14, 2022

SELL
$72.5 - $100.68 $26.8 Million - $37.2 Million
-369,000 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$90.24 - $124.05 $19.9 Million - $27.4 Million
-221,000 Reduced 37.46%
369,000 $35.2 Million
Q2 2021

Aug 16, 2021

SELL
$93.66 - $139.27 $749,280 - $1.11 Million
-8,000 Reduced 1.34%
590,000 $73.3 Million
Q1 2021

May 17, 2021

BUY
$116.57 - $155.01 $40.9 Million - $54.4 Million
351,000 Added 142.11%
598,000 $78.8 Million
Q4 2020

Feb 16, 2021

BUY
$99.61 - $142.12 $24.6 Million - $35.1 Million
247,000 New
247,000 $32.7 Million
Q1 2020

May 15, 2020

SELL
$37.9 - $104.44 $1.17 Million - $3.24 Million
-31,000 Closed
0 $0
Q4 2019

Jun 17, 2020

BUY
$77.66 - $99.74 $2.41 Million - $3.09 Million
31,000 New
31,000 $2.87 Million

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $8.77B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Avidity Partners Management LP Portfolio

Follow Avidity Partners Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Avidity Partners Management LP with notifications on news.